Previous 10 | Next 10 |
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2023. Unless otherwise stated, all comparisons are for the second quarter of 2023 compared to the second quarter of 2022. Product revenue, net consists entir...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 3, 2023, following the release of its second quarter 2023 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
2023-07-17 00:09:34 ET Summary Puma Biotechnology reported a net product revenue of $46.8 million in Q1 2023, an increase from $40.7 million in Q1 2022, and shifted from a net loss to a net income. Despite promising growth and profitability metrics, Puma Biotechnology is expected ...
A significant medical breakthrough is needed in the fight against metastatic breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of invasive breast cancer. However, there’s hope for treatment, with companies like BriaCe...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone (Clinicatrials.gov identifier NCT02187991) in metastatic hormone receptor positive (HR+) and triple neg...
A significant medical breakthrough is desperately needed in the fight against metastatic breast cancer. As it stands right now, metastatic breast cancer has no cure and has proven resistant to many cancer treatments. However, there may be hope on the horizon for the 43,000 women that die every ye...
2023-05-22 17:30:42 ET Gainers: Movella Holdings ( MVLA ) +14% . Trevi Therapeutics ( TRVI ) +5% . QUALCOMM ( QCOM ) +5% . Galera Therapeutics ( GRTX ) +4% . LivePerson ( LPSN ) +4% . Losers: Guardant Health (...
A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone have a history of invasive breast cancer. And unfortunately, as it stands, breast cancer dea...
2023-05-04 22:54:08 ET Puma Biotechnology, Inc. (PBYI) Q1 2023 Earnings Conference Call May 4, 2023, 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chairman, President and CEO Maximo Nougues - Chief Financi...
2023-05-04 16:48:10 ET Puma Biotechnology press release ( NASDAQ: PBYI ): Q1 Non-GAAP EPS of $0.09. Revenue of $52.8M (+15.5% Y/Y). For further details see: Puma Biotechnology Non-GAAP EPS of $0.09, revenue of $52.8M
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000 ® Index at the conclusion of Russell Investments’ annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S....